ReviewEuropean respiratory review : an official journal of the European Respiratory Society2024
The persistent inflammation in COPD: is autoimmunity the core mechanism?
Review in European respiratory review : an official journal of the European Respiratory Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 33 citations in OpenAlex.
- Host-pathogen interactions in tuberculosis: from immunological mechanisms to translational applications.Cell insight · 2026Review
- Article
- Relationship between the advanced lung cancer inflammation index (ALI) and all-cause and cause-specific mortality among patients with chronic obstructive pulmonary disease (COPD): a population-based study.BMC pulmonary medicine · 2026Article
- Article
- Integrated Network Toxicology and Metabolomics Elucidate Mechanisms of Carbosulfan-Induced Respiratory Toxicity in Rats.International journal of molecular sciences · 2026Article
- Elevated C-Reactive Protein-Albumin-Lymphocyte Index Is Associated With Reduced Mortality in Chronic Inflammatory Airway Diseases: A Population-Based Observational Study.Mediators of inflammation · 2026Observational
- Effective-Component Compatibility of Bufei Yishen Formula Alleviates Alveolar Epithelial Barrier Damage in COPD Through Inhibition of p38 MAPK Phosphorylation.International journal of chronic obstructive pulmonary disease · 2026Article
- Piezo1 in respiratory diseases: mechanotransduction, cell-specific functions, and translational implications.Frontiers in physiology · 2026Review
- Association between the C-reactive protein-albumin-lymphocyte index and incident depression in patients with chronic obstructive pulmonary disease: a prospective cohort study from the UK biobank.Frontiers in medicine · 2026Article
- Chronic obstructive pulmonary disease (COPD) and autoimmune diseases: unravelling complex interactions.Annals of medicine · 2025Review
- Biological Therapies in Chronic Obstructive Pulmonary Disease: New Directions in Personalised Respiratory Medicine.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Radiomic Signatures in COPD: The Need to Integrate Eosinophilic and Autoimmune Endotypes.Chest · 2025Article
- Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits.Respiratory research · 2025Review
- Transcriptome reveals the landscape of alveolar macrophages exposed to combined hypoxia with cigarette smoke extract.Respiratory research · 2025Article
- Identification of STAT3 signaling as a shared pathogenic signature in systemic lupus erythematosus, chronic obstructive pulmonary disease, and asthma.Scientific reports · 2025Article
- Towards early detection and disease interception of COPD across the lifespan.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Healthcare environments in pulmonary rehabilitation units: Effective -infection control through integration of long-term antimicrobial materials.Multidisciplinary respiratory medicine · 2025Article
- Anthocyanin-Rich Fraction from Kum Akha Black Rice Attenuates NLRP3 Inflammasome-Driven Lung Inflammation In Vitro and In Vivo.Nutrients · 2025Article
- Defining a non-eosinophilic inflammatory subtype in COPD: the role of CXCL9 and type 1 immune responses.Frontiers in immunology · 2025Article
- Trapping DNA Radicals With DMPO Reduces Hypochlorous Acid-Induced 8-oxo-7,8-dihydro-2'-deoxyguanosine and Mutagenesis in Lung Epithelial Cells.Oxidative medicine and cellular longevity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COPD poses a significant global public health challenge, primarily characterised by irreversible airflow restriction and persistent respiratory symptoms. The hallmark pathology of COPD includes sustained airway inflammation and the eventual destruction of lung tissue structure. While multiple risk factors are implicated in the disease's progression, the underlying mechanisms remain largely elusive. The perpetuation of inflammation is pivotal to the advancement of COPD, emphasising the importance of investigating these self-sustaining mechanisms for a deeper understanding of the pathogenesis. Autoimmune responses constitute a critical mechanism in maintaining inflammation, with burgeoning evidence pointing to their central role in COPD progression; yet, the intricacies of these mechanisms remain inadequately defined. This review elaborates on the evidence supporting the presence of autoimmune processes in COPD and examines the potential mechanisms through which autoimmune responses may drive the chronic inflammation characteristic of the disease. Moreover, we attempt to interpret the clinical manifestations of COPD through autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.